Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Drug/Agent Toxicity by Tissue/Organ|Endometrial Cancer|Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
Interventions: DIETARY_SUPPLEMENT: pyridoxine hydrochloride|DRUG: Placebo|DRUG: doxorubicin HCL liposome
Sponsor: Case Comprehensive Cancer Center
Collaborators: National Cancer Institute (NCI)